DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) -- (https://247mnn.com/) – ClearOne (NASDAQ: CLRO), NeOnc Technologies (NASDAQ: NTHI), Iovance Biotherapeutics (NASDAQ:IOVA), and Ensysce Biosciences (NASDAQ:ENSC) are covered in today’s roundup.
ClearOne Advances Toward Neurotechnology Transformation
ClearOne (NASDAQ:CLRO) continues moving closer to completing its planned transformation into a neurotechnology company as new SEC filings remove several key uncertainties surrounding its pending acquisition of Cortigent, a wholly owned subsidiary of Vivani Medical (NASDAQ:VANI), which was first announced on July 2, as investors continue tracking milestones that could reshape the company's future.
ClearOne's latest Form 8-K disclosed several notable steps supporting the transaction. The company entered into a warrant cancellation agreement eliminating warrants covering 437,500 shares at a $5.00 exercise price, simplifying its capital structure ahead of closing. ClearOne also finalized an employment agreement with incoming Chief Financial Officer Simon Brewer, whose appointment becomes effective upon completion of the Cortigent acquisition, reinforcing preparations for the combined company's next phase.
Perhaps most significantly, ClearOne disclosed that majority shareholder First Finance Ltd., which controls approximately 61.3% of the company's voting power, has already approved the transaction through written consent. The approval authorizes the issuance of 12.5 million shares required for the merger while also adopting the company's 2026 Omnibus Incentive Plan. Although procedural requirements remain, including mailing a Schedule 14C information statement before the share issuance becomes effective, the transaction has effectively cleared one of its largest shareholder hurdles.
The acquisition represents a dramatic strategic pivot. Upon closing, ClearOne expects to rename itself Cortigent Holdings and trade under the new ticker NASDAQ: CRGT. Vivani Medical is expected to become the majority owner of the combined company, while Cortigent's management team will lead operations as an independent neurotechnology business.
Investor interest continues to center on Cortigent's precision neurostimulation platform. The company previously commercialized the FDA-approved Argus II retinal prosthesis and is now advancing the investigational Orion cortical visual prosthesis, which has received FDA Breakthrough Device Designation for treating blindness caused by glaucoma, diabetic retinopathy, and other conditions. Cortigent is also developing implantable neurostimulation technologies designed to restore arm and hand function following stroke, expanding the platform into additional neurological indications.
The combined company also plans to complete a concurrent financing expected to raise between $10 million and $15 million, providing additional capital to advance Cortigent's pipeline. While the transaction remains subject to customary closing conditions, including financing completion and continued Nasdaq listing, recent corporate actions suggest management continues to execute toward its targeted third-quarter 2026 closing.
NeOnc Technologies Approaches Multiple Clinical and Regulatory Catalysts
NeOnc Technologies (NASDAQ:NTHI) is entering what could become one of its most catalyst-rich periods as investors await topline Phase 2a data from the fully enrolled NEO100-01 study. The company has positioned NEO100 within multiple expedited regulatory pathways after receiving FDA Orphan Drug, Fast Track, and Rare Pediatric Disease Designations, potentially providing meaningful development advantages if clinical data remain supportive.
The company continues emphasizing that future FDA interactions will depend on forthcoming clinical results and that regulatory decisions remain subject to independent FDA review. Investors are expected to focus on efficacy, safety, and potential next-step guidance as Phase 2a data become available.
NeOnc has also expanded internationally after receiving a second Investigational New Drug (IND) authorization from the Department of Health – Abu Dhabi, allowing additional studies evaluating NEO100 for recurrent high-grade gliomas. The authorization complements the company's previously announced UAE approval for NEO212, further expanding its international clinical footprint.
Investor attention has also focused on insider activity and institutional ownership. Recent SEC filings show Chairman, President and CEO Amir Heshmatpour has invested more than $500,000 through open-market purchases, with insider buying approaching $1 million over the past year. Public filings also identify institutions including Bank of America, State Street, Barclays, and BlackRock among shareholders. Combined with previously disclosed financing facilities and multiple anticipated regulatory milestones during 2026, NeOnc remains closely watched within the CNS oncology sector.
Iovance Biotherapeutics Delivers Record Revenue While Expanding Cell Therapy Pipeline
Iovance Biotherapeutics (NASDAQ:IOVA) reported record second-quarter 2026 revenue of approximately $99.3 million, representing 66% year-over-year growth, driven primarily by continued adoption of Amtagvi, the company's FDA-approved tumor infiltrating lymphocyte (TIL) therapy for advanced melanoma. Gross margin improved to 56%, reflecting manufacturing efficiencies and higher commercial volumes.
Based on stronger-than-expected demand trends, management announced it is reviewing previously issued 2026 revenue guidance of $350 million to $370 million, with an updated outlook expected during the third quarter. The company also continues expanding its authorized treatment center network while pursuing international regulatory approvals across Australia, the United Kingdom, Switzerland, and additional global markets.
Beyond commercialization, Iovance continues advancing one of the industry's broadest TIL therapy pipelines. Recent milestones include FDA Fast Track Designation for lifileucel in soft tissue sarcomas, continued enrollment across multiple registrational studies, and expansion into additional solid tumor indications including non-small-cell lung cancer and endometrial cancer.
Supported by approximately $304 million in cash as of June 30, 2026, management expects current resources to fund operations into the second half of 2028 while continuing to invest in manufacturing expansion, artificial intelligence initiatives, and next-generation engineered TIL programs.
Ensysce Expands Pipeline with Cy Biopharma Acquisition and Up To $77M Financing
Ensysce Biosciences (NASDAQ:ENSC) has significantly expanded its clinical pipeline through the acquisition of privately held Cy Biopharma, adding a clinical-stage neuroplastogenic therapy targeting Complex Regional Pain Syndrome (CRPS) Type 1 while securing financing that could total up to $77 million.
The acquisition adds CY200, which has received FDA Orphan Drug Designation for CRPS, a debilitating chronic pain disorder with no FDA-approved therapies specifically indicated for the condition. Management believes the transaction positions the combined company to advance CY200 through Phase 2 proof-of-concept studies and into registrational development while leveraging potential regulatory incentives associated with orphan designation.
The transaction also substantially strengthens Ensysce's balance sheet. Funding includes approximately $17.1 million in cash acquired through Cy Biopharma's pre-acquisition financing, an additional $21.5 million expected through the initial private placement led by Ally Bridge Group, and a potential $38.6 million milestone-based financing tranche tied to future clinical progress. The financing is intended to shift the company's focus toward clinical execution rather than near-term capital raising.
Importantly, Ensysce plans to continue advancing PF614-MPAR, its abuse-resistant opioid candidate utilizing the company's proprietary TAAP™ and MPAR® technologies. That program continues receiving financial support from the National Institute on Drug Abuse (NIDA), allowing the company to pursue both next-generation opioid safety technologies and novel non-opioid neuroplastogenic therapies. With CY200 Phase 2 development and PF614-MPAR progressing simultaneously, investors are expected to closely monitor multiple upcoming clinical catalysts.
Sources
- ClearOne SEC Form 8-K (August 2026): https://www.sec.gov/
- ClearOne Merger Announcement: https://www.clearone.com/
- Cortigent: https://www.cortigent.com/
- Vivani Medical: https://www.vivani.com/
- NeOnc Technologies: https://www.neonc.com/
- Iovance Biotherapeutics Q2 2026 Results: https://ir.iovance.com/
- Ensysce Biosciences: https://www.ensysce.com/
- Cy Biopharma: https://www.cybiopharma.com/
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor. For the full disclosure, please visit:
For further information, please visit https://247mnn.com/.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
